View Online | View on mobile
![]() | POEMs Research Summaries Your DAILY UPDATE for the Latest Patient Oriented Evidence that Matters |
| Omega-3s do not prevent CV disease
Bottom Line Supplementing with omega-3 fatty acids does not decrease the likelihood of a subsequent cardiovascular event in patients with preexisting cardiovascular disease over the course of 1 year. (LOE = 1a) Reference Kwak SM, Myung SK, Lee YJ, Seo HG, for the Korean Meta-analysis Study Group. Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease. A meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012;172(9):686-694.
Synopsis The authors conducting this meta-analysis searched several databases, including the Cochrane Library, and identified 14 studies enrolling a total of 20,485 patients with a history of cardiovascular disease. The patients to were randomized to receive omega-3 supplements for 1 year in most studies (the longest study lasted 5 years). Two investigators independently selected studies for inclusion. Study quality was assessed with the frequently used Jadad scale, which found most studies to be of high quality. The authors found homogeneity among most of the studies and no evidence of publication bias. They used the "all bad things" outcome as their primary measure to determine whether patients were less likely to experience one of a number of cardiovascular outcomes ranging from more important -- cardiovascular death, stroke, myocardial infarction -- to less important, such as tranisent ischemic attack, angina, and peripheral vascular disease. Mixing these apples and oranges could affect the statistics. Supplementation did not reduce the risk of overall cardiovascular events. Individually, the only outcome that was significantly affected was cardiovascular death, though this effect was lost when a single study with possible methodologic problems was removed from the analysis. Results did not differ when the authors analyzed the results by dose of the supplement, duration of follow-up, or study quality. Allen F. Shaughnessy, PharmD | |||||||||||||||
![]() ![]() ![]()
| ||||||||||||||||
Copyright © 2011 by Wiley Subscription Services, Inc. All rights reserved. This is an automated email. Replies will be ignored. Copyright © 2011 by Wiley Subscription Services, Inc. All rights reserved. www.essentialevidenceplus.com. |
Hiç yorum yok:
Yorum Gönder